Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986196 DDI Study in Healthy Participants
NCT05852769Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2023
- Primary completion
- Aug 2023
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 11c-bms-986196 in multiple sclerosis (MS), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 26 days, Area under the plasma concentration-time curve extrapolated to infinite time up to 26 days and 1 more. Started May 2023; status: completed.
02
Drugs
11c-bms-986196
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05852769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05852769.